fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

New UH study targets early signs of vision loss in diabetic patients

Written by | 21 Aug 2024

A $3.3 million study at the University of Houston College of Optometry will track the health of patients with prediabetes and diabetes to find out who might develop… read more.

European Commission approves Vabysmo (faricimab) for treatment of retinal vein occlusion – Roche

Written by | 2 Aug 2024

Roche announced that the European Commission (EC) has approved Vabysmo (faricimab) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO, branch… read more.

CHMP recommends Vevizye (cyclosporine 0.05 in SFA) to treat dry eye disease – Novaliq GmbH

Written by | 31 Jul 2024

On 25 July 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.

Popular prescription weight loss drugs linked to uncommon blinding condition

Written by | 14 Jul 2024

A new study led by investigators from Mass Eye and Ear found that patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of… read more.

Biocon Biologics obtains FDA approval for biosimilar aflibercept for Yesafili and enters U.S. ophthalmology market

Written by | 9 Jul 2024

Biocon Biologics Ltd (BBL),announced that the FDA has approved the Company’s first-to-file application for Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor… read more.

CHMP positive for Vabysmo (faricimab) marketing authorisation to include the treatment of visual impairment due to macular edema secondary to retinal vein occlusion – Roche

Written by | 3 Jul 2024

Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the Vabysmo (faricimab) marketing… read more.

European Commission authorization for Lytenava (bevacizumab gamma) for the treatment of Wet AMD – Outlook Therapeutics

Written by | 20 Jun 2024

Outlook Therapeutics, Inc., a biopharmaceutical company focused on the commercialization and development of ONs-5010/Lytenava (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, announced that the European Commission… read more.

‘Smart’ contact lenses could someday enable wireless glaucoma detection

Written by | 11 May 2024

Most people with early-stage glaucoma don’t know they have it, even though early treatment is key to reducing vision loss. While detecting a subtle increase in eye pressure… read more.

Artificial intelligence to be used for the detection of common eye disease

Written by | 25 Apr 2024

Dry Eye Disease (DED) is one of the more common eye diseases, affecting up to 30% of the world’s population. This disease can affect many different types of… read more.

Organic compound found in trees could prevent contact lens eye infections

Written by | 11 Feb 2024

A new study suggests a naturally-occurring material is an effective disinfectant for contact lenses, worn by millions of people worldwide. Microbial keratitis is one of the most serious… read more.

Study reveals untapped potential to increase eye donations needed for sight-restoring surgeries

Written by | 4 Nov 2023

A new study has found there is significant scope to increase the number of eye donations from patients cared for in hospice and palliative care settings – donations… read more.

LianBio announces topline results from phase III LIBRA trial of TP 03 in Chinese patients with Demodex blepharitis

Written by | 3 Nov 2023

LianBio a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced topline results from the Phase III LIBRA clinical trial… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.